NICE recommends abiraterone for prostate cancer after manufacturer reduces priceBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e3520 (Published 18 May 2012) Cite this as: BMJ 2012;344:e3520
- Zosia Kmietowicz
The National Institute for Health and Clinical Excellence (NICE) has amended draft guidance on the drug abiraterone (marketed in the United Kingdom as Zytiga) for men with advanced prostate cancer after the manufacturer agreed a reduced price deal for the NHS.
Abiraterone, which is made by Janssen, was initially rejected by NICE for use in England and Wales in draft guidance launched in February because it was too expensive.1 But after negotiations with Janssen the guidance has been reissued, although the discount offered to the NHS on the drug—which costs £2930 (€3650; $4640) for a month’s supply—has been kept confidential for commercial reasons. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial